BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CERAM Publishes Two New White Papers on Multi-Substituted Hydroxyapatite


6/14/2013 9:40:17 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

14 June 2013 – Stoke-on-Trent, UK - As part of its ongoing work on biocompatibility and bioactivity of Hydroxyapatite (HA), Ceram, the international materials technology company, has published two new white papers, ‘Regulatory Approval Testing of Hydroxyapatite’ and ‘Synthesis Methods of Hydroxyapatite’.

Gaining and maintaining regulatory approval of medical devices and materials, such as Hydroxyapatite (HA) can be a fraught, lengthy and complex process. Submission of data to regulatory bodies, for example the FDA (Food and Drug Administration), has to be credible and fully documented in order to ensure success. In the regulatory approval white paper, Gemma Budd, Product Manager, Healthcare at Ceram, argues the case for using one supplier for regulatory approval testing, using the example of HA testing.

The other white paper looks at various synthesis methods of HA, including precipitation, sol-gel and self-propagating combustion and demonstrates the vast variability of HA synthesised by some of the most popular methodologies. With its newly-patented technology, Ceram’s aim is to work with clients to develop HA with tailored bioactivity, both for bone replacement materials applications and for new drug delivery systems with tailored bio-application requirements. The white papers are free to download from Ceram’s website at www.ceram.com/medical.

About Ceram

Ceram is an independent, international materials technology company that operates in a wide variety of sectors around the world.

Headquartered in Staffordshire, UK, and with approved laboratories around the world, Ceram solves product and process challenges across a range of materials to help clients improve performance, comply with regulations and manage resource efficiency in order to gain a competitive advantage and increase profitability.

Mandy

Mandy Rymill

Marketing Communications Manager

Tel. 44 (0)1782 764326

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES